The present invention concerns an oral solution comprising the MTP inhibitor mitratapide or a pharmaceutically acceptable acid addition salt thereof, a process for preparing such solutions, and their use in the treatment of MTP-related disorders such as hyperlipidemia, obesity, or type II diabetes.
